Historically, the clinical research community has been slow to adopt decentralized or hybrid trial models. There are many overall benefits of decentralized/hybrid trials and remote monitoring: increased enrollment and retention of patients in clinical studies, the reduction of administrative burdens on sponsors and investigators and the ability for patients to receive treatments from their community providers without compromising study quality or data integrity.

The COVID-19 pandemic has made these benefits even more obvious, and as travel restrictions, social distancing and the overall strain on the healthcare system became more evident, the FDA updated regulations to fast-track research, openly recognizing the value of alternative technology such as virtual trial capabilities in clinical research.

This webinar will explore how COVID-19 pushed the industry to adapt to tech-enabled solutions for patients and sponsors.

When you need direct access to physicians and their known patients or research practice management solutions to accelerate your clinical trials, there’s Only Elligo.

Contact Us